- Home
- FLYE vs KZIA Comparison
FLYE vs KZIA Comparison
Compare FLYE & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYE
- KZIA
- Stock Information
- Founded
- FLYE 2018
- KZIA 1994
- Country
- FLYE United States
- KZIA Australia
- Employees
- FLYE N/A
- KZIA N/A
- Industry
- FLYE Aerospace
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- FLYE Industrials
- KZIA Health Care
- Exchange
- FLYE Nasdaq
- KZIA Nasdaq
- Market Cap
- FLYE 91.6M
- KZIA 9.0M
- IPO Year
- FLYE 2024
- KZIA 1999
- Fundamental
- Price
- FLYE $0.66
- KZIA $7.03
- Analyst Decision
- FLYE
- KZIA Strong Buy
- Analyst Count
- FLYE 0
- KZIA 3
- Target Price
- FLYE N/A
- KZIA $16.00
- AVG Volume (30 Days)
- FLYE 487.8K
- KZIA 188.3K
- Earning Date
- FLYE 11-18-2025
- KZIA 11-14-2025
- Dividend Yield
- FLYE N/A
- KZIA N/A
- EPS Growth
- FLYE N/A
- KZIA N/A
- EPS
- FLYE N/A
- KZIA N/A
- Revenue
- FLYE $22,881,935.00
- KZIA $1,549,158.00
- Revenue This Year
- FLYE N/A
- KZIA N/A
- Revenue Next Year
- FLYE N/A
- KZIA $49.25
- P/E Ratio
- FLYE N/A
- KZIA N/A
- Revenue Growth
- FLYE N/A
- KZIA 248983.08
- 52 Week Low
- FLYE $0.48
- KZIA $2.86
- 52 Week High
- FLYE $8.30
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- FLYE 41.73
- KZIA 49.80
- Support Level
- FLYE $0.48
- KZIA $6.82
- Resistance Level
- FLYE $0.72
- KZIA $7.29
- Average True Range (ATR)
- FLYE 0.06
- KZIA 0.46
- MACD
- FLYE 0.05
- KZIA 0.06
- Stochastic Oscillator
- FLYE 70.31
- KZIA 59.21
About FLYE Fly-E Group Inc. Common Stock
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.